Shionogi EPS - Earnings per Share 2021-2023 | SGIOY

Shionogi earnings per share (EPS) for the twelve months ending December 31, 2023 was $0.49, a 80% increase year-over-year.

  • Shionogi EPS for the quarter ending December 31, 2023 was $0.00, a 100% decline year-over-year.
  • Shionogi 2024 annual EPS was $0.64, a 16.19% decline from 2023.
  • Shionogi 2023 annual EPS was $0.77, a 36.3% increase from 2022.
  • Shionogi 2022 annual EPS was $0.56, a 1.75% decline from 2021.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.

Shionogi EPS - Earnings per Share 2021-2023 | SGIOY

  • Shionogi EPS for the quarter ending December 31, 2023 was $0.00, a 100% decline year-over-year.
  • Shionogi 2024 annual EPS was $0.64, a 16.19% decline from 2023.
  • Shionogi 2023 annual EPS was $0.77, a 36.3% increase from 2022.
  • Shionogi 2022 annual EPS was $0.56, a 1.75% decline from 2021.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$79.2B
Takeda Pharmaceutical (TAK)$43.3B
Sandoz Group AG (SDZNY)$19.5B
Merck (MKKGY)$19.2B
Astellas Pharma (ALPMY)$18.2B
United Therapeutics (UTHR)$16.1B
Summit Therapeutics (SMMT)$14.7B
Neurocrine Biosciences (NBIX)$12.1B
Catalent (CTLT)$10.7B
Jazz Pharmaceuticals (JAZZ)$7.1B
Madrigal Pharmaceuticals (MDGL)$6.9B
Orion OYJ (ORINY)$6.7B
Corcept Therapeutics (CORT)$5.7B
Ionis Pharmaceuticals (IONS)$5.3B
Crinetics Pharmaceuticals (CRNX)$5.1B
PTC Therapeutics (PTCT)$3B
Dyne Therapeutics (DYN)$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
Arrowhead Pharmaceuticals (ARWR)$2.3B
Soleno Therapeutics (SLNO)$2.2B
NewAmsterdam Pharma (NAMS)$2.2B
Centessa Pharmaceuticals (CNTA)$1.9B
Evotec AG (EVO)$1.8B
Recursion Pharmaceuticals (RXRX)$1.8B
Xencor (XNCR)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.5B
Indivior (INDV)$1.4B
Harrow (HROW)$1.4B
Ocular Therapeutix (OCUL)$1.4B